Profound Medical (TSE:PRN) Stock Price Down 2.1% - Here's Why

Key Points

• Profound Medical Corp. saw its stock price drop by 2.1% on Monday, trading between C$5.59 and C$5.63.
• The company's market capitalization is C$169.20 million, with a negative PE ratio of -3.88 and significant liquidity indicated by a quick ratio of 14.98.
• Profound Medical develops incision-free therapeutic systems for the image-guided ablation of diseased tissue, with its lead product being the TULSA-PRO system.

Profound Medical Corp. (TSE:PRN - )'s stock price dropped 2.1% during mid-day trading on Monday . The stock traded as low as C$5.59 and last traded at C$5.63. Approximately 17,464 shares were traded during trading, an increase of 119% from the average daily volume of 7,990 shares. The stock had previously closed at C$5.75.

Profound Medical Stock Performance

The company has a market cap of C$169.20 million, a PE ratio of -3.88 and a beta of -0.25. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The company has a 50-day moving average of C$7.30 and a 200-day moving average of C$7.76.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.